Skip to content

Study of cress seed extract on knee osteoarthritis

Study of topical formulation of cress seed extract (Lepidium sativum L.) on knee osteoarthritis: a randomized double-blind clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160913029802N4
Enrollment
72
Registered
2025-06-02
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Participants in the intervention group will receive a topical formulation containing garden cress (Lepidium sativum) seed extract. The medication will be applied tw

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: "Patients aged 40 years and older with primary knee osteoarthritis who present with mild to moderate knee joint pain (up to a maximum score of 7 on the Visual Analogue Scale [VAS]), and whose diagnosis of osteoarthritis has been confirmed based on the American College of Rheumatology (ACR) criteria. Patients with no prior history of joint replacement No history of acute or uncontrolled conditions such as gastrointestinal bleeding, uncontrolled hypertension, or myocardial and cerebrovascular infarctions within the past six months, etc. No use of nonsteroidal anti-inflammatory drugs (NSAIDs) or oral corticosteroids within 14 days prior to the study, and no use of injectable forms within 30 days prior to the study BMI<35Kg/m^2

Exclusion criteria

Exclusion criteria: Hypersensitivity to the plant or its constituents Occurrence of an unexpected adverse effect Low patient recruitment and lack of cooperation

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: At baseline, and at 14 and 28 days after the start of treatment. Method of measurement: VAS score.

Secondary

MeasureTime frame
Joint stiffness. Timepoint: At baseline, and at 28 days after the start of treatment. Method of measurement: WOMAC scale.;Assessment of physical functioning and the ability to perform activities of daily living. Timepoint: At baseline, and at 28 days after the start of treatment. Method of measurement: WOMAC scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyde Sedighe Yousefi

Mazandaran University of Medical Sciences

s.yousefi@mazums.ac.ir+98 11 3324 4893

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026